Fig. 5: TRAC-KO is only relevant to reduce unspecific cytotoxicity in JMML but not the U937 model.
From: Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
A Quantified bioluminescence imaging of U937 histiocytic lymphoma model in NSG mice treated with regular or TRAC-KO CAR or UTD T cells, n = 5/arm except n = 1 for PBS. B Survival curve for the same study as in (A). C Bioluminescence images for the same study as in (A). Note increased scale for bioluminescence measurements at later timepoints. D Flow cytometric analysis showing the number of remaining live GFP− CD14+ JMML cells (normalized to UTD T cells) after co-culture with CAR or control T cells for 24 h at different E:T (n = 3 technical triplicates). Statistical analysis was performed by two-way ANOVA with Tukey’s multiple comparisons test. p-values: empty vs. empty KO E:T 1:27 = 0.0001, ****<0.0001. avg radiance average radiance.
